Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neuroprotective Effects of Poly(ADP-ribose)polymerase Inhibitor Olaparib in Transient Cerebral Ischemia
Authors
Keywords
Blood–brain barrier, Ischemic stroke, Olaparib, Poly(ADP-ribose)polymerase
Journal
NEUROCHEMICAL RESEARCH
Volume 41, Issue 7, Pages 1516-1526
Publisher
Springer Nature
Online
2016-02-12
DOI
10.1007/s11064-016-1864-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca2+ Permeable α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
- (2015) Elisabetta Gerace et al. CNS & Neurological Disorders-Drug Targets
- Safety evaluation of olaparib for treating ovarian cancer
- (2015) Stephanie Lheureux et al. Expert Opinion On Drug Safety
- Chromosomal damage and micronucleus induction by MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor: Evidence for a non-DNA-reactive mode of action
- (2015) Eiji Yamamura et al. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
- Intranasal delivery of progesterone after transient ischemic stroke decreases mortality and provides neuroprotection
- (2015) Magalie Fréchou et al. NEUROPHARMACOLOGY
- Poly(ADP-ribose) Polymerase-1 Inhibition in Brain Endothelium Protects the Blood—Brain Barrier under Physiologic and Neuroinflammatory Conditions
- (2014) Slava Rom et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities
- (2013) Amos A Fatokun et al. BRITISH JOURNAL OF PHARMACOLOGY
- Prevention of rt-PA induced blood–brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice
- (2013) Fei Teng et al. EXPERIMENTAL NEUROLOGY
- Mild activation of poly(ADP-ribose) polymerase (PARP) is neuroprotective in rat hippocampal slice models of ischemic tolerance
- (2012) Elisabetta Gerace et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke
- (2012) Mohamad El Amki et al. EXPERIMENTAL NEUROLOGY
- Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
- (2012) Joanna M Wardlaw et al. LANCET
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Christopher J L Murray et al. LANCET
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Rafael Lozano et al. LANCET
- Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
- (2012) Jenna L. Riffell et al. NATURE REVIEWS DRUG DISCOVERY
- The role of PARP in DNA repair and its therapeutic exploitation
- (2011) M Javle et al. BRITISH JOURNAL OF CANCER
- Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase
- (2011) F Moroni et al. BRITISH JOURNAL OF PHARMACOLOGY
- Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse
- (2011) Jean-Christophe Copin et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
- (2011) Martin D. Forster et al. Nature Reviews Clinical Oncology
- Poly(ADP-Ribose) (PAR) Binding to Apoptosis-Inducing Factor Is Critical for PAR Polymerase-1-Dependent Cell Death (Parthanatos)
- (2011) Y. Wang et al. Science Signaling
- Progesterone and allopregnanolone attenuate blood–brain barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases
- (2010) Tauheed Ishrat et al. EXPERIMENTAL NEUROLOGY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications
- (2010) Rupinder K. Sodhi et al. VASCULAR PHARMACOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase Suppresses Inflammation and Promotes Recovery after Ischemic Injury
- (2009) Tiina M Kauppinen et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose)polymerase inhibitor, after permanent focal cerebral ischemia in mice
- (2008) Marianne Haddad et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage
- (2007) F MORONI CURRENT OPINION IN PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now